Italian health officials have approved reimbursement for vamorolone, a new treatment for Duchenne muscular dystrophy, marking a significant step in expanding access to innovative therapies for this rare genetic condition.
The Italian Medicines Agency (AIFA) announced on April 22, 2026, that its Administrative Council granted reimbursement status to Agamree (vamorolone), a first-in-class steroidal anti-inflammatory drug designed to provide the therapeutic benefits of glucocorticoids even as reducing the risk of adverse effects commonly associated with steroid use.
Vamorolone is indicated for patients aged four years and older with Duchenne muscular dystrophy, a progressive muscle-wasting disease that leads to loss of mobility, respiratory and cardiac complications, and shortened life expectancy.
The approval was part of a broader decision by AIFA to reimburse four new medicines, extend indications for nine existing therapies, and approve six generic equivalents. Other newly reimbursed medications include Nemluvio (nemolizumab) for atopic dermatitis and prurigo nodularis, Trecondi (treosulfan) for hematopoietic stem cell transplantation preparation, and Welireg (belzutifan) for certain cancers associated with von Hippel-Lindau disease.
This development follows earlier clinical research showing dose-related improvements in muscle function among boys with Duchenne muscular dystrophy treated with vamorolone, as reported in a 2019 open-label, multiple-ascending-dose study conducted across multiple international sites.
By making vamorolone available through the national health system, Italian authorities aim to improve access to a treatment option that balances efficacy with a potentially safer long-term profile for children living with this debilitating condition.
